1949JAMARequires access

MODIFIED PROTAMINE INSULIN (NPH-50)

Priscilla White

Open publisher page 4 citations

Abstract

This article is a clinical report on the use of modified protamine insulin (NPH-50)—first, what it is; second, why it is indicated; third, how does it differ from present market insulins; fourth, what has been the experience of the Joslin Clinic in its use; fifth, what technics have been employed in its administration, and, sixth, what are its failures as well as its successes? Insulin of the NPH-50 type contains protamine modified by crystallization. Neutral in reaction, it is designated N; protamine, it is termed P; improved by Hagedorn, it is named H; modified by the addition of 0.50 mg. of crystallized protamine for every 100 units of insulin, it is tagged 50—therefore, NPH-50 insulin. New modifications of insulin are being and should be sought. Wonderful though insulin is, the forms now available have three obvious defects; first, their administration is parenteral; second, their time of action is too slow,

About this research paper

What this paper is about

This article is a clinical report on the use of modified protamine insulin (NPH-50)—first, what it is; second, why it is indicated; third, how does it differ from present market insulins; fourth, what has been the experience of the Joslin Clinic in its use; fifth, what technics have been employed in its administration, and, sixth, what are its failures as well as its successes? Insulin of the NPH-50 type contains protamine modified by crystallization. Neutral in reaction, it is designated N; protamine, it is termed P; improved by Hagedorn, it is named H; modified by the addition of 0.50 mg. of crystallized protamine for every 100 units of insulin, it is tagged 50—therefore, NPH-50 insulin. New modifications of insulin are being and should be sought. Wonderful though insulin is, the forms now available have three obvious defects; first, their administration is parenteral; second, their time of action is too slow,

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

This article is a clinical report on the use of modified protamine insulin (NPH-50)—first, what it is; second, why it is indicated; third, how does it differ from present market insulins; fourth, what has been the experience of the Joslin Clinic in its use; fifth, what technics have been employed in its administration, and, sixth, what are its failures as well as its successes? Insulin of the NPH-50 type contains protamine modified by crystallization. Neutral in reaction, it is designated N; protamine, it is termed P; improved by Hagedorn, it is named H; modified by the addition of 0.50 mg. of crystallized protamine for every 100 units of insulin, it is tagged 50—therefore, NPH-50 insulin. New modifications of insulin are being and should be sought. Wonderful though insulin is, the forms now available have three obvious defects; first, their administration is parenteral; second, their time of action is too slow,

Key concepts: Protamine, NPH insulin, Insulin, Internal medicine, Medicine, Endocrinology, Heparin, Insulin glargine

Related papers

Back to paper searchBrowse research topicsOriginal source
MODIFIED PROTAMINE INSULIN (NPH-50) — Research Paper | ScholarLens